News

PaxMedica Secures Immediate Exercise of Warrants

TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No.

09/03/2024

PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, (HAT), commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home.

08/27/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is PaxMedica, Inc. Common Stock (PXMD) a buy, sell, or hold?

PaxMedica, Inc. Common Stock (PXMD) can sell. Click on Rating Page for detail.

What is PaxMedica, Inc. Common Stock's stock price?

The price of PaxMedica, Inc. Common Stock (PXMD) is 0.12 and it was updated on 2024-09-26 11:01:06.

Is PaxMedica, Inc. Common Stock (PXMD) overvalued or undervalued?

Currently PaxMedica, Inc. Common Stock (PXMD) is in undervalued.

News

From:

To:

News
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) ( OTC:PXMD ), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq. Following receipt of notification from Nasdaq on April 30th, PaxMedica determined to appeal the decision and intends to maintain that the Hearings Panel did not consider sufficiently or appropriately crucial aspects of PaxMedica's recent achievements and ongoing actions to regain compliance with all applicable requirements for continued listing. PaxMedica has retained Jacob Frenkel, Dickinson Wright, PLLC as its lead counsel in the appeal, working with the consulting firm that interacted previously with the Hearings Panel. Wed, May. 15, 2024
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (MOH) of Malawi, a country in east Africa. The request seeks emergency access to the Company's recently completed registration batches of PAX-101 (IV suramin) to address the critical shortage of medications required to combat the life-threatening sleeping sickness, also known as Trypanosoma brucei rhodesiense, Human African trypanosomiasis (TBr HAT), crisis in the region. Tue, Apr. 23, 2024
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa. Tue, Apr. 16, 2024
Choosing Unknown Penny Stocks, 3 Top Tips Penny stocks represent an exciting opportunity for investors looking to expand their portfolios with potentially lucrative, yet cost-effective options. Typically trading below five dollars per share, these stocks offer a gateway into investing with a smaller upfront financial commitment. Mon, Apr. 15, 2024
Why is PaxMedica (PXMD) stock surging today? PaxMedica (NASDAQ: PXMD) has surged by 92.7% so far on Friday, reflecting the market's positive reaction to the company's announcement of significant progress in its drug development efforts. Fri, Apr. 12, 2024

SEC Filings

SEC Filings
PaxMedica, Inc. Common Stock (PXMD) - 10-Q - Quarterly Report SEC Filings 09/20/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 09/06/2024
PaxMedica, Inc. Common Stock (PXMD) - NT 10-Q - Quarterly Report SEC Filings 08/14/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 07/19/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 06/14/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 05/28/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 05/15/2024
PaxMedica, Inc. Common Stock (PXMD) - 10-Q - Quarterly Report SEC Filings 05/13/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 05/01/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 04/23/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 04/16/2024
PaxMedica, Inc. Common Stock (PXMD) - DEF 14A SEC Filings 04/15/2024
PaxMedica, Inc. Common Stock (PXMD) - ARS SEC Filings 04/15/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 04/11/2024
PaxMedica, Inc. Common Stock (PXMD) - PRE 14A SEC Filings 04/03/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 03/22/2024
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 03/14/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 03/13/2024
PaxMedica, Inc. Common Stock (PXMD) - 10-K - Current report SEC Filings 03/11/2024
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 02/23/2024
PaxMedica, Inc. Common Stock (PXMD) - SC 13G/A SEC Filings 02/13/2024
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 01/31/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 01/29/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 01/12/2024
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 12/21/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 11/30/2023
PaxMedica, Inc. Common Stock (PXMD) - SC 13G SEC Filings 11/29/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 11/29/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 11/29/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 11/22/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 11/22/2023
PaxMedica, Inc. Common Stock (PXMD) - EFFECT SEC Filings 11/21/2023
PaxMedica, Inc. Common Stock (PXMD) - 424B4 SEC Filings 11/21/2023
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 11/16/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 11/16/2023
PaxMedica, Inc. Common Stock (PXMD) - 10-Q - Quarterly Report SEC Filings 11/16/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 11/15/2023
PaxMedica, Inc. Common Stock (PXMD) - S-1 SEC Filings 11/09/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 11/09/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 10/30/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 10/30/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 10/24/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 10/04/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 09/27/2023
PaxMedica, Inc. Common Stock (PXMD) - DEF 14A SEC Filings 09/11/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 09/06/2023
PaxMedica, Inc. Common Stock (PXMD) - PRE 14A SEC Filings 09/01/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 08/30/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 08/23/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 08/17/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 08/16/2023
PaxMedica, Inc. Common Stock (PXMD) - 3 SEC Filings 08/16/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 08/09/2023
PaxMedica, Inc. Common Stock (PXMD) - 10-Q - Quarterly Report SEC Filings 08/09/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 08/04/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 07/28/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 07/24/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 07/06/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 06/16/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 06/08/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 06/02/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 05/15/2023
PaxMedica, Inc. Common Stock (PXMD) - 10-Q - Quarterly Report SEC Filings 05/15/2023
PaxMedica, Inc. Common Stock (PXMD) - EFFECT SEC Filings 05/12/2023
PaxMedica, Inc. Common Stock (PXMD) - 424B3 SEC Filings 05/11/2023
PaxMedica, Inc. Common Stock (PXMD) - S-1 SEC Filings 05/04/2023
PaxMedica, Inc. Common Stock (PXMD) - 4/A SEC Filings 05/01/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 04/28/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 04/28/2023
PaxMedica, Inc. Common Stock (PXMD) - DEFR14A SEC Filings 04/24/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 04/14/2023
PaxMedica, Inc. Common Stock (PXMD) - ARS SEC Filings 04/07/2023
PaxMedica, Inc. Common Stock (PXMD) - 424B3 SEC Filings 04/07/2023
PaxMedica, Inc. Common Stock (PXMD) - EFFECT SEC Filings 04/06/2023
PaxMedica, Inc. Common Stock (PXMD) - DEF 14A SEC Filings 04/06/2023
PaxMedica, Inc. Common Stock (PXMD) - S-8 SEC Filings 04/05/2023
PaxMedica, Inc. Common Stock (PXMD) - POS AM SEC Filings 04/05/2023
PaxMedica, Inc. Common Stock (PXMD) - PRE 14A SEC Filings 03/31/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 03/30/2023
PaxMedica, Inc. Common Stock (PXMD) - 10-K - Current report SEC Filings 03/30/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 03/09/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 03/07/2023
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 03/03/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 02/15/2023
PaxMedica, Inc. Common Stock (PXMD) - 424B3 SEC Filings 02/15/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 02/07/2023
PaxMedica, Inc. Common Stock (PXMD) - 424B3 SEC Filings 02/07/2023
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 01/06/2023
PaxMedica, Inc. Common Stock (PXMD) - 424B3 SEC Filings 01/06/2023
PaxMedica, Inc. Common Stock (PXMD) - EFFECT SEC Filings 12/28/2022
PaxMedica, Inc. Common Stock (PXMD) - 424B3 SEC Filings 12/27/2022
PaxMedica, Inc. Common Stock (PXMD) - S-1 SEC Filings 12/19/2022
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 12/19/2022
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 12/09/2022
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 11/22/2022
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 11/21/2022
PaxMedica, Inc. Common Stock (PXMD) - 10-Q - Quarterly Report SEC Filings 11/14/2022
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 11/08/2022
PaxMedica, Inc. Common Stock (PXMD) - 3/A SEC Filings 10/14/2022
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 10/12/2022
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 10/04/2022
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 10/03/2022
PaxMedica, Inc. Common Stock (PXMD) - 10-Q - Quarterly Report SEC Filings 09/30/2022
PaxMedica, Inc. Common Stock (PXMD) - NT 10-Q - Quarterly Report SEC Filings 09/26/2022
PaxMedica, Inc. Common Stock (PXMD) - SC 13G SEC Filings 09/09/2022
PaxMedica, Inc. Common Stock (PXMD) - SC 13D SEC Filings 09/09/2022
PaxMedica, Inc. Common Stock (PXMD) - 4 SEC Filings 09/01/2022
PaxMedica, Inc. Common Stock (PXMD) - S-8 SEC Filings 08/31/2022
PaxMedica, Inc. Common Stock (PXMD) - 8-K - Current report SEC Filings 08/30/2022
PaxMedica, Inc. Common Stock (PXMD) - 424B4 SEC Filings 08/29/2022
PaxMedica, Inc. Common Stock (PXMD) - EFFECT SEC Filings 08/15/2022
PaxMedica, Inc. Common Stock (PXMD) - CERT SEC Filings 08/12/2022
PaxMedica, Inc. Common Stock (PXMD) - 3 SEC Filings 08/12/2022
PaxMedica, Inc. Common Stock (PXMD) - CORRESP SEC Filings 08/11/2022
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 08/10/2022
PaxMedica, Inc. Common Stock (PXMD) - 8-A12B SEC Filings 08/10/2022
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 08/08/2022
PaxMedica, Inc. Common Stock (PXMD) - CORRESP SEC Filings 08/08/2022
PaxMedica, Inc. Common Stock (PXMD) - SEC STAFF LETTER SEC Filings 08/04/2022
PaxMedica, Inc. Common Stock (PXMD) - UPLOAD SEC Filings 07/26/2022
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 07/19/2022
PaxMedica, Inc. Common Stock (PXMD) - CORRESP SEC Filings 07/18/2022
PaxMedica, Inc. Common Stock (PXMD) - UPLOAD SEC Filings 07/06/2022
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 06/10/2022
PaxMedica, Inc. Common Stock (PXMD) - CORRESP SEC Filings 06/10/2022
PaxMedica, Inc. Common Stock (PXMD) - D SEC Filings 05/10/2022
PaxMedica, Inc. Common Stock (PXMD) - UPLOAD SEC Filings 02/02/2022
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 01/04/2022
PaxMedica, Inc. Common Stock (PXMD) - D SEC Filings 11/06/2020
PaxMedica, Inc. Common Stock (PXMD) - UPLOAD SEC Filings 10/02/2020
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 09/29/2020
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 09/15/2020
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 09/14/2020
PaxMedica, Inc. Common Stock (PXMD) - CORRESP SEC Filings 09/14/2020
PaxMedica, Inc. Common Stock (PXMD) - UPLOAD SEC Filings 09/10/2020
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 09/02/2020
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 08/28/2020
PaxMedica, Inc. Common Stock (PXMD) - FWP SEC Filings 08/28/2020
PaxMedica, Inc. Common Stock (PXMD) - CORRESP SEC Filings 08/27/2020
PaxMedica, Inc. Common Stock (PXMD) - SEC STAFF LETTER SEC Filings 08/07/2020
PaxMedica, Inc. Common Stock (PXMD) - UPLOAD SEC Filings 08/03/2020
PaxMedica, Inc. Common Stock (PXMD) - S-1/A SEC Filings 07/23/2020
PaxMedica, Inc. Common Stock (PXMD) - CORRESP SEC Filings 07/23/2020
PaxMedica, Inc. Common Stock (PXMD) - UPLOAD SEC Filings 07/17/2020
PaxMedica, Inc. Common Stock (PXMD) - S-1 SEC Filings 07/02/2020
PaxMedica, Inc. Common Stock (PXMD) - CORRESP SEC Filings 07/02/2020
PaxMedica, Inc. Common Stock (PXMD) - UPLOAD SEC Filings 06/12/2020
PaxMedica, Inc. Common Stock (PXMD) - DRS SEC Filings 05/15/2020

Press Releases

StockPrice Release
Paxmedica secures immediate exercise of warrants 09/03/2024
Paxmedica reports first patient treated with pax-101 for fatal african sleeping sickness infection 08/27/2024
Paxmedica files nasdaq delisting appeal notice and prepares for upcoming fda meeting on pax-101 05/15/2024
Paxmedica responds to emergency request for iv suramin and commits to provide immediate access to pax-101 04/23/2024
Paxmedica receives emergency request for iv suramin from african health ministry for use in treating fatal sleeping sickness 04/16/2024
Paxmedica achieves key milestone in the development of pax-101 and provides update on potential nda submission 04/11/2024
Paxmedica updated company presentation highlighting innovations in autism spectrum disorder treatments 03/13/2024
Paxmedica releases fireside chat video with ceo howard weisman 12/06/2023
Paxmedica announces closing of $7.0 million public offering 11/22/2023
Paxmedica announces pricing of $7.0 million public offering 11/20/2023
Paxmedica inc. featured in syndicated broadcast highlighting fda type-b meeting to review pax-101 pivotal trial data 11/17/2023
Paxmedica, inc. announces third quarter 2023 financial results and business update 11/15/2023
Paxmedica announces publication of its autism spectrum disorder phase 2 study results in peer-reviewed journal 11/07/2023
Paxmedica engages bourne partners to explore future monetization of potential priority review voucher (prv) 11/02/2023
Paxmedica acquires suramin research assets from rediscovery life sciences to accelerate nda submission for pax-101 10/31/2023
Paxmedica announces 1-for-17 reverse stock split 10/30/2023
Paxmedica's research on low dose suramin for autism spectrum disorder accepted for publication 10/26/2023
Paxmedica to present at the h.c. wainwright 25th annual global investment conference 08/30/2023
Paxmedica appoints david hough m.d. as chief medical officer 08/16/2023
Paxmedica, inc. announces second quarter 2023 financial results and business update 08/09/2023
Paxmedica to join fireside chat with pcg advisory following positive top line results from pax-hat-301 study 08/08/2023
Paxmedica announces positive top line results from the pax-101 (intravenous suramin) phase 3 african sleeping sickness study, pax-hat-301 07/24/2023
Paxmedica grants exclusive pharmacy distribution rights for pax-101 to vox nova, llc 07/06/2023
Paxmedica comments on common stock volatility 06/22/2023
Paxmedica ceo interviewed by the brain foundation 06/20/2023
Paxmedica submits clinical trial request in autism spectrum disorder 06/14/2023
Paxmedica enters research collaboration agreement with polomar health for phase ii study in autism spectrum disorder 06/08/2023
Paxmedica completes hat-301 registrational trial for pax-101 06/01/2023
Paxmedica announces nasdaq closing bell ringing to celebrate initial public offering and autism awareness month 04/19/2023
Paxmedica, inc. provides business update and reports fourth quarter 2022 financial results 03/29/2023
Paxmedica holds meeting of scientific advisory board 03/20/2023
Paxmedica releases 2022 shareholder letter 02/15/2023
Paxmedica, inc. secures $3.2 million growth capital from lind partners 02/03/2023
Paxmedica to present at the jan 26th virtual investor summit microcap event 01/20/2023
Paxmedica, inc. launches updated corporate website at paxmedica.com 12/14/2022
Paxmedica to present at the benchmark company's upcoming discovery one-on-one investor conference 11/22/2022
Paxmedica, inc. enters into committed equity investment agreement for up to $20 million with lincoln park capital 11/17/2022
Paxmedica, inc. provides business update and reports third quarter 2022 financial results 11/15/2022
Paxmedica initiates clinical program to advance pax-101 towards fda submission 11/08/2022
Paxmedica appoints stefan schwabe md, phd as chief medical officer 10/24/2022
Paxmedica appoints specialty pharma industry leader charles j. casamento to its board of directors 10/03/2022
Paxmedica, inc. provides corporate update after ipo 09/27/2022
Craft capital management announces pricing of initial public offering for paxmedica, inc. 08/26/2022
Paxmedica, inc. announces pricing of initial public offering 08/26/2022

More Headlines

News
Why Is PaxMedica (PXMD) Stock Up 93% Today? PaxMedica (NASDAQ: PXMD ) stock is rocketing higher on Friday after the clinical-stage biopharmaceutical company reached a key milestone in drug development. The big news here is the company securing three pivotal registration/validation batches of PAX-101. 04/12/2024
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement is an important milestone to enabling a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), which is currently planned for Q4 2024, and for the potential commercial availability in the U.S. of the first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei rhodesiense, a fatal, neglected tropical disease, if approved by the FDA. 04/11/2024
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica's strategic direction, recent advancements in ASD therapeutics, and its commitment to addressing unmet needs within the ASD community. 03/13/2024
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Fireside Chat video featuring Howard Weisman, Chairman and CEO. Overview: In this comprehensive company update video, Mr. 12/06/2023
PaxMedica Announces Closing of $7.0 Million Public Offering TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the closing of its previously announced public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants have an exercise price of $1.30 per share, are exercisable immediately upon issuance, and will expire five years after the initial exercise date. 11/22/2023
Why Are Stocks Up Today? Stocks are up today as investors prepare for a Thanksgiving holiday with the latest insight into the economy from the Federal Reserve. The Fed released its meeting minutes yesterday and it offers insight into the agency's future plans. 11/22/2023
Penny Stocks To Buy? 5 To Watch Right Now Penny stocks refer to shares of small or micro-cap companies that trade for less than $5 per share. What cheap stocks lack in size and stability, they can potentially make up for in rapid price changes and explosive short-term gains. 11/22/2023
Why Is PaxMedica (PXMD) Stock Up 57% Today? PaxMedica (NASDAQ: PXMD ) stock is climbing higher on Wednesday after the company completed a public offering for its shares. According to a press release from the company, it's offering 5,384,615 shares of PXMD stock at a price of $1.30 per share. 11/22/2023
Why Is PaxMedica (PXMD) Stock Down 40% Today? PaxMedica (NASDAQ: PXMD ) stock is cratering today after the company announced a $7 million public offering. The offering consists of 5.38 million shares and warrants to purchase up to 5.38 million shares. 11/20/2023
PaxMedica Announces Pricing of $7.0 Million Public Offering TARRYTOWN, NY / ACCESSWIRE / November 20, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a combined public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $1.30 per share, will be exercisable immediately upon issuance, and will expire five years after the initial exercise date. 11/20/2023
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers PaxMedica's recent announcement of the completion of a type-B meeting with the FDA. During the live meeting, the company discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated. 11/17/2023
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensive business update along with its financial results for the third quarter ended September 30, 2023. Key Updates and Achievements Successfully concluded a crucial FDA Type-B meeting, gathering vital guidance for the NDA submission of PAX-101. 11/15/2023
Why Is PaxMedica (PXMD) Stock Up 95% Today? PaxMedica (NASDAQ: PXMD ) stock is rising higher on Tuesday as investors celebrate the company's publication of Phase 2 clinical trial results. The study was published in the Annals of General Psychiatry and focused on the use of low-dose suramin intravenous infusions as a treatment for Autism Spectrum Disorder (ASD). 11/07/2023
Penny Stocks To Buy Now? 3 to Watch With Big News Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime. 11/07/2023
Why Is PaxMedica (PXMD) Stock Up Today? PaxMedica (NASDAQ: PXMD ) stock is jumping significantly higher against the backdrop of another soft session on Wall Street. This morning, management announced a productive discussion with the U.S. Food and Drug Administration (FDA) over positive clinical trial results for a key drug. 10/26/2023
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for the market. 10/26/2023
PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference Presentation on Tuesday, September 12, 2023 at 3:00pm EDT TARRYTOWN, NY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that it will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY. 08/30/2023
Why Is PaxMedica (PXMD) Stock Up Today? Clinical-stage biopharmaceutical firm PaxMedica (NASDAQ: PXMD ) is experiencing a full range of emotions following an initial spike in the market today. Earlier this morning, the company announced encouraging top-line results from its Phase 3 trial of PAX-101 (intravenous suramin), which met its primary endpoint. 07/24/2023
PaxMedia hires ShareIntel to look into recent stock weakness, after a 45% plunge amid an 8-day losing streak Shares of PaxMedia Inc. PXMD, -11.91% bounced 2.0% in premarket trading Thursday, after the biopharmaceutical company, which focuses on treatments of Autism Spectrum Disorder (ASD) said it was not aware of any news that might have led to the recent selloff in its stock. The company said it has hired Shareholder Intelligence Services LLC (ShareIntel) to look into the recent price fluctuations. 06/22/2023
Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch Short squeeze penny stocks to watch. The post Best Penny Stocks To Buy? 03/10/2023
Are Penny Stocks on Your February Watchlist? 3 Reasons to Buy Should penny stocks be on your watchlist? The post Are Penny Stocks on Your February Watchlist? 02/06/2023
Deciding Which Penny Stocks to Buy? Use These 3 Tips Here's some tips for deciding which penny stocks are worth buying The post Deciding Which Penny Stocks to Buy? Use These 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 02/05/2023
Why Is PaxMedica (PXMD) Stock Up Today? What caused a pop-and-drop in PaxMedica (NASDAQ: PXMD ) stock today? PaxMedica is in the headlines due to an arrangement that will reportedly generate over $3 million for the company. 02/03/2023
Penny Stocks To Buy: 4 To Watch With Big News In February Penny stocks with news to watch this week. The post Penny Stocks To Buy: 4 To Watch With Big News In February appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 02/03/2023
Short Squeeze Stocks: 5 Stocks Wall Street Really DOESN'T Want to Win Retail investors have taken a particular interest in potential short-squeeze stocks ever since the onset of the coronavirus pandemic. At that time, meme stock favorite GameStop (NYSE: GME ) squeezed to unimaginable levels, wreaking havoc on Wall Street investors with short positions. 01/25/2023
Top 5 most-shorted stocks as of January 2023 The macroeconomic climate in 2022 and 2023 has had a negative impact on many equity investments. Fears of a possible recession and a gloomy attitude among investors have affected companies in precarious financial situations. 01/24/2023
3 Short Squeeze Penny Stocks To Watch Before 2023 Short squeeze penny stocks to watch. The post 3 Short Squeeze Penny Stocks To Watch Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 12/28/2022
Best Penny Stocks To Buy? 7 Short Squeeze Stocks To Watch Now Penny stocks to watch with higher short interest right now. The post Best Penny Stocks To Buy? 12/02/2022
PaxMedica to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference TARRYTOWN, NY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced it will be presenting at the Benchmark Company's 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022 at the New York Athletic Club in New York City. 11/22/2022
PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week We're checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market! Short squeeze stocks are often subject to volatility with massive gains. 11/21/2022
Are Penny Stocks too Risky to Invest In? 3 Reasons to Consider Check out these reasons to buy penny stocks in 2022 The post Are Penny Stocks too Risky to Invest In? 3 Reasons to Consider appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 11/21/2022
Thinking Of Buying Penny Stocks? Here's What to Look For Understand these tips for finding penny stocks to buy The post Thinking Of Buying Penny Stocks? Here's What to Look For appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 11/19/2022
Why Is PaxMedica (PXMD) Stock Up 51% Today? PaxMedica (NASDAQ: PXMD ) stock is taking off on Friday after the biopharmaceutical company entered into an investment agreement with Lincoln Park Capital Fund. According to a press release, this covers a purchase agreement and registration rights agreement for up to $20 million. 11/18/2022
A Major Squeeze Is Brewing in PaxMedica (PXMD) Stock PaxMedica (NASDAQ: PXMD ) stock could be preparing for a short squeeze with recent signs showing potential for it to surge in price. Let's start off with the basics, which include the company completing its initial public offering ( IPO ) near the end of August. 10/24/2022
Best Penny Stocks To Buy Now? 4 Low Float Stocks To Watch This Week Low float penny stocks to watch this week. The post Best Penny Stocks To Buy Now? 10/19/2022
Penny Stocks To Buy: 4 Stocks Under $5 To Watch This Week Hot penny stocks to buy for under $5 but are they worth the risk? The post Penny Stocks To Buy: 4 Stocks Under $5 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 09/27/2022
Hot Penny Stocks to Buy After the Long Weekend? 3 to Watch Which penny stocks are on your watchlist today? The post Hot Penny Stocks to Buy After the Long Weekend? 09/06/2022
Trending Penny Stocks For Your September Watchlist Here's what you need to know about trading penny stocks on September 2nd The post Trending Penny Stocks For Your September Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 09/02/2022
Why Are Shipping Stocks Down Today? Source: Darryl Brooks / Shutterstock.com Shipping stocks are sinking on Friday as reports come in that U.S. ports are still having trouble following turbulence during the pandemic. Shipping companies have been dealing with problems ever since the pandemic started. 08/26/2022
Is PaxMedica (PXMD) Stock the Next Hot IPO? IPO season continues today with another exciting entrant. PaxMedica (NASDAQ: PXMD ) is the newest company to make its public debut. 08/26/2022

Unlock

PXMD Ratings Summary

PXMD Quant Ranking